Optimization of Therapy in Patients with Paranoid Schizophrenia and Non-suicidal Autoaggression who have recovered from Coronavirus Infection
Article Sidebar
Main Article Content
Abstract
The issue of comorbidity of coronavirus infection and chronic mental disorders remains an important medical problem, determining the relevance of the study. A continuous, non-randomized method was used to conduct a comparative analysis of combination therapy in 124 patients with paranoid schizophrenia with non-suicidal autoaggressive behavior (abbreviated NAAB) who have had coronavirus infection. A clinical method and experimental psychometric research methods were used, including brief psychiatric assessment scales; social functioning scales and a visual analog pain scale. The clinical picture features during the period of remote consequences of the transferred coronavirus infection in the examined persons were established. It was established that antipsychotics in combination with non-steroidal anti-inflammatory drugs have a positive clinical effect in the examined persons.
Moreover, additional administration of drugs with osmotic dehydrating activity statistically significantly increases the clinical effect of the treatment in relation to the leading psychopathological features, including NSAB in this group of patients.
Article Details
Copyright (c) 2026 Kravchenko IV, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
1. Al-Kuraishy HM, Al-Gareeb AI, Al-Maiahy TJ, Alexiou A, Mukerjee N, Batiha GE. Prostaglandins and non-steroidal anti-inflammatory drugs in COVID-19. Biotechnol Genet Eng Rev. 2024;40(4):3305-3325. Epub 2022. Available from: https://doi.org/10.1080/02648725.2022.2122290
2. Barlattani T, Celenza G, Cavatassi A, Minutillo F, Socci V, Pinci C, et al. Neuropsychiatric manifestations of COVID-19 disease and post COVID syndrome: the role of N acetyl-cysteine and acetyl-L-carnitine. Curr Neuropharmacol. 2024. Epub ahead of print. Available from: https://doi.org/10.2174/011570159x343115241030094848
3. Nlandu Y, Tannor EK, Bafemika T, Makulo JR. Kidney damage associated with COVID-19: from the acute to the chronic phase. Ren Fail. 2024;46(1):2316885. Epub 2024. Available from: https://doi.org/10.1080/0886022x.2024.2316885
4. Tassone D, Thompson A, Connell W, Lee T, Ungaro R, An P, et al. Immunosuppression as a risk factor for COVID-19: a meta-analysis. Intern Med J. 2021;51(2):199-205. Available from: https://doi.org/10.1111/imj.15142
5. Peluso MJ, Deeks SG. Mechanisms of long COVID and the path toward therapeutics. Cell. 2024. Available from: https://doi.org/10.1016/j.cell.2024.07.054
6. Huntington SF, Lin D, Lafeuille MH, Thompson-Leduc P, Shah A, Kim N, et al. Identification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapy. Pharmacol Res Perspect. 2024;12(6):e70024. Available from: https://doi.org/10.1002/prp2.70024
7. Raza ML, Imam MH, Zehra W, Jamil S. Neuro-inflammatory pathways in COVID-19-induced central nervous system injury: implications for prevention and treatment strategies. Exp Neurol. 2024;382:114984. Epub 2024. Available from: https://doi.org/10.1016/j.expneurol.2024.114984
8. Maury A, Lyoubi A, Peiffer-Smadja N, de Broucker T, Meppiel E. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: a narrative review for clinicians. Rev Neurol (Paris). 2021;177:51-64. Available from: https://doi.org/10.1016/j.neurol.2020.10.001
9. Tian T, Wu J, Chen T, Li J, Yan S, Zhou Y, et al. Long-term follow-up of dynamic brain changes in patients recovered from COVID-19 without neurological manifestations. JCI Insight. 2022;7(4):e155827. Available from: https://doi.org/10.1172/jci.insight.155827
10. Li C, Verduzco-Gutierrez M. Neurologic and neuromuscular sequelae of COVID-19. Phys Med Rehabil Clin N Am. 2023;34(3):539-549. Epub 2023 Apr 6. Available from: https://doi.org/10.1016/j.pmr.2023.04.002
11. Bohmwald K, Diethelm-Varela B, Rodríguez-Guilarte L, Rivera T, Riedel CA, González PA, et al. Pathophysiological, immunological, and inflammatory features of long COVID. Front Immunol. 2024;15:1341600. Available from: https://doi.org/10.3389/fimmu.2024.1341600
12. Can B, Oz S, Sahinturk V, Musmul A, Alatas İO. Effects of conivaptan versus mannitol on post-ischemic brain injury and edema. Eurasian J Med. 2019;51(1):42-48. Available from: https://doi.org/10.5152/eurasianjmed.2019.18368
13. Cook AM, Morgan Jones G, Hawryluk GWJ, Mailloux P, McLaughlin D, Papangelou A, et al. Guidelines for the acute treatment of cerebral edema in neurocritical care patients. Neurocrit Care. 2020;32(3):647-666. Available from: https://doi.org/10.1007/s12028-020-00959-7
14. Dabrowski W, Siwicka-Gieroba D, Robba C, Bielacz M, Sołek-Pastuszka J, Kotfis K, et al. Potentially detrimental effects of hyperosmolality in patients treated for traumatic brain injury. J Clin Med. 2021;10(18):4141. Available from: https://doi.org/10.3390/jcm10184141
15. Methodological recommendations “Prevention, diagnosis and treatment of the new coronavirus infection COVID-19”, version 7, 03 Jun 2020.
16. Solodov AA, Petrikov SS. Effect of hyperosmolar solutions on intracranial and cerebral perfusion pressure in patients with non-traumatic intracranial hemorrhages. Rus Neurosurgical Journal named after prof. A.L. Polenov. 2009;4(4):59-65.
17. Beach SR, Luccarelli J, Praschan N, Fusunyan M, Fricchione GL. Molecular and immunological origins of catatonia. Schizophr Res. 2024;263:169-177. Epub 2023 Mar 23. Available from: https://doi.org/10.1016/j.schres.2023.03.013
18. Dawood AS, Dawood A, Dawood S. Catatonia after COVID-19 infection: scoping review. BJPsych Bull. 2023;47(4):208-219. Available from: https://doi.org/10.1192/bjb.2022.30
19. Redon M, Virolle J, Montastruc F, Taïb S, Revet A, Da Costa J, et al. The use of antipsychotics in the treatment of catatonia: a systematic review. Eur Psychiatry. 2025;68(1):e48. Available from: https://doi.org/10.1192/j.eurpsy.2025.9
20. Swain CA, Robbs EJ, Verma L, Brandt H, Seppaenen AL, Cavnar PJ. Characterization of the atypical antipsychotic drug aripiprazole cytotoxicity in the neutrophil model cell line HL-60. PLoS One. 2025;20(2):e0318878. Available from: https://doi.org/10.1371/journal.pone.0318878
21. Acioglu C, Elkabes S. Innate immune sensors and regulators at the blood brain barrier: focus on toll-like receptors and inflammasomes as mediators of neuro-immune crosstalk and inflammation. J Neuroinflammation. 2025;22(1):39. Available from: https://doi.org/10.1186/s12974-025-03360-3
22. Fekete M, Lehoczki A, Szappanos Á, Toth A, Mahdi M, Sótonyi P, et al. Cerebromicrovascular mechanisms contributing to long COVID: implications for neurocognitive health. Geroscience. 2025;47(1):745-779. Epub 2025 Jan 7. Available from: https://doi.org/10.1007/s11357-024-01487-4
23. Talkington GM, Kolluru P, Gressett TE, Ismael S, Meenakshi U, Acquarone M, et al. Neurological sequelae of long COVID: a comprehensive review of diagnostic imaging, underlying mechanisms, and potential therapeutics. Front Neurol. 2025;15:1465787. Available from: https://doi.org/10.3389/fneur.2024.1465787
24. Klyushnik TP, Zozulya SA. Immunology of schizophrenia: a modern view on inflammatory hypotheses of the disease. Psychiatry (Moscow). 2024;22(4):14-25. Available from: https://doi.org/10.30629/2618-6667-2024-22-4-14-25